CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis.
CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis.
复制标题
CD133 表达与结直肠癌的预后：系统回顾和荟萃分析
DOI：
10.1371/journal.pone.0056380
复制
发表时间：
2013
期刊：
影响因子：
3.7
通讯作者：
Li J
中科院分区：
文献类型：
--
作者：
Chen S;Song X;Chen Z;Li X;Li M;Liu H;Li J
CD133最近被报道是结直肠癌（CRC）的癌症样细胞的标记，但是，在这项研究中，CRC中的预测值仍然存在争议。以及CRC患者通过进行荟萃分析的结果。
使用PubMed，Medline和ISI Web的综合研究进行了迄今为止的相关研究。软件。
我们发现，共有15项涉及810个CD133高的研究和1487名CD133-LOW患者符合5年总生存率（OS）率的纳入标准。大肠癌中的高表达是一种独立的预后标记，与OS率相关（RR = 0.67，95％CI 0.54-0.82，P <0.01）和无疾病生存（DFS）速率（RR = 0.71，95％CI 0.52-0.96，p = 0.03）。 CI 1.01–1.23，p = 0.03），1.31（95％CI 1.06–1.63，p = 0.01）和1.24（95％CI 1.08–1.41，p <0.01）。但是，当考虑组织学类型，淋巴侵袭和远处转移时，CD133的过表达与这些临床病理学参数没有显着相关。
我们的荟萃分析结果表明，CD133是CRC较高的CD133表达的有效预后因素。
Objective CD133 has recently been reported as a marker of cancer stem-like cells in colorectal cancer (CRC). However, its predictive value in CRC still remains controversial. In this study, we aimed to evaluate the association between the expression of CD133 and clinicopathological features and the outcome of CRC patients by performing a meta-analysis. Methods A comprehensive literature search for relevant studies published up to December 2012 was performed using PubMed, MEDLINE and ISI Web of Science. Only articles in which CD133 antigen was detected in situ localisation by immunohistochemical staining were included. This meta-analysis was done using RevMan 4.2 software. Results We found that a total of 15 studies involving 810 CD133-high and 1487 CD133-low patients met the inclusion criteria for the analysis of 5-year overall survival (OS) rate. In a random-effects model, the results showed that CD133-high expression in colorectal cancer was an independent prognostic marker correlating with both OS rate (RR = 0.67, 95%CI 0.54–0.82, P<0.01) and disease free survival (DFS) rate (RR = 0.71, 95%CI 0.52–0.96, P = 0.03). CD133-high expression was also associated with more T3,4 tumor invasion, N positive and vascular invasion cases, corresponding to a risk difference of 1.12 (95%CI 1.01–1.23, P = 0.03), 1.31 (95%CI 1.06–1.63, P = 0.01) and 1.24 (95%CI 1.08–1.41, P<0.01), respectively. However, when types of histology, lymphatic invasion and distant metastasis were considered, CD133 overexpression was not significantly related with these clinicopathological parameters. Conclusion Our meta-analysis results suggest that CD133 is an efficient prognostic factor in CRC. Higher CD133 expression is significantly associated with poorer clinical outcome and some clinicopathological factors such as T category, N category and vascular invasion in CRC patients.